CDMOs/CMOs Expand High-Potency API Manufacturing

Growth in the oncology drug market continues to spur demand for high-potency API manufacturing. Which CDMOs/CMOs are expanding? DCAT Value Chain Insights rounds up the latest investments. For the text version of this article visit dcatvci.org.

Key topics: (see Chapter Markers in drop down menu in audio player above)

• A roundup of recent investments in HPAPI manufacturing
•  WuXi STA
•  MilliporeSigma
• Piramal Pharma Solutions
• Cambrex
• HAS Healthcare Advanced Synthesis
• AGC Fine Chemicals
• Lonza
• Carbogen Amcis
• Sterling Pharma Solutions
• Ajinomoto Bio-Pharma Services
• Novasep
• Olon
• Cerbios-Pharma
• Formosa Laboratories
• Sai Life Sciences
• BSP Pharmaceuticals
• Seqens
• CordenPharma

 

Sponsor: BIOVECTRA

 

Links:

Subscribe to our e-newsletter at www.dcatvci.org

Follow us on Twitter @DCATvci

Support the show 

Support the show